Anbio Biotechnology
NNNN
5 hedge funds and large institutions have $937K invested in Anbio Biotechnology in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
89% more capital invested
Capital invested by funds: $496K → $937K (+$441K)
67% more funds holding
Funds holding: 3 → 5 (+2)
0.08% less ownership
Funds ownership: 0.15% → 0.07% (-0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$47.4K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$12.1K |
| 3 |
Morgan Stanley
New York
|
+$3.83K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$957 |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$670 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$325K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $542K | +$670 | +70 | +0.4% |
|
|
2
UBS Group
Zurich,
Switzerland
| $339K | +$47.4K | +4,957 | +86% |
|
|
3
BNP Paribas Financial Markets
Paris,
France
| $39.9K | +$12.1K | +1,261 | New |
|
|
4
Morgan Stanley
New York
| $12.7K | +$3.83K | +400 | New |
|
|
5
Wells Fargo
San Francisco,
California
| $3.17K | +$957 | +100 | New |
|
|
6
Marshall Wace
London,
United Kingdom
| – | -$325K | -43,629 | Closed |
|
NNNN Hedge Fund Activity: Q2 2025 in Review
5 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Anbio Biotechnology (NNNN) for Q2 2025, worth a combined $937K — up 89% from $496K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NNNN positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $47.4K. The largest seller was Marshall Wace, exiting entirely with an estimated $325K sold.
- 5 institutional investors held Anbio Biotechnology (NNNN) as of Q2 2025, up from 3 in Q1 2025.
- Funds reported $937K of Anbio Biotechnology stock for Q2 2025, up 89% quarter-over-quarter.
- 3 funds opened new Anbio Biotechnology positions in Q2 2025 and 1 closed out, a net change of +2 holders.
- The largest Anbio Biotechnology buyer in Q2 2025 was UBS Group, an estimated $47.4K added.
- The largest Anbio Biotechnology seller in Q2 2025 was Marshall Wace, an estimated $325K sold.
Based on aggregated 13F filings for Q2 2025.